Unified Patents v. Pogona LLC

U.S. Patent No. 11,058,757, owned by Pogona LLC, is currently the subject of an inter partes review (IPR) proceeding, IPR2026-00189, before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO). While the prompt identifies Unified Patents as the petitioner, web search results confirm that Pfizer Inc. is the petitioner in this specific IPR. Unified Patents is a member-based organization focused on deterring non-practicing entities (NPEs), often referred to as "patent trolls," from asserting low-quality patents by challenging their validity through IPRs. Given that Pogona LLC is the patent owner being challenged by major pharmaceutical companies, it is likely perceived as a Patent Assertion Entity by the petitioners.

The patent at issue, U.S. Patent No. 11,058,757, is titled "Saccharide-polypeptide conjugate compositions and methods of use thereof." This patent covers pharmaceutical compositions that include multiple unique immunogenic saccharide-polypeptide conjugates. These conjugates specifically utilize capsular polysaccharides from various Streptococcus pneumoniae serotypes, which are linked to a polypeptide, indicating the patent's relevance to pneumococcal vaccine technology.

The procedural posture of this case is an inter partes review before the PTAB, designated IPR2026-00189. The PTAB granted institution of the IPR on May 25, 2026, meaning the Board has found sufficient grounds to proceed with a full review of the patent's validity. The PTAB is a critical administrative forum for challenging patent validity, often preferred by accused infringers due to its streamlined procedures compared to district court litigation. This case is particularly notable because U.S. Patent No. 11,058,757 is also being challenged by other major pharmaceutical companies, including Merck Sharp & Dohme LLC, which filed a separate IPR (IPR2026-00221) against the same patent. The combined efforts of leading pharmaceutical companies like Pfizer and Merck to invalidate this patent highlight its potential impact on the pneumococcal vaccine market and suggest underlying litigation or significant licensing disputes in this vital public health sector.

The provided case, Unified Patents v. Pogona LLC, IPR2026-00189, is an Inter Partes Review (IPR) before the Patent Trial and Appeal Board (PTAB), not a district court patent infringement litigation. IPRs are administrative proceedings challenging the patentability of claims, which can run parallel to, or influence, district court litigation. Therefore, certain litigation-specific milestones like complaints, answers, trials, and jury verdicts are not applicable to the IPR itself.

As of today, May 29, 2026, the IPR is still pending.

Here's a summary of the known legal developments related to IPR2026-00189 and any related district court litigation involving U.S. Patent No. 11,058,757:

1. Parallel District Court Litigation (Precursor to IPR)

Before detailing the IPR, it's common for IPRs to be filed in response to assertions of a patent in district court. Searching for litigation involving U.S. Patent No. 11,058,757 and Pogona LLC reveals several district court cases where Pogona LLC has asserted this patent.

• Initial Filings:

  • Pogona LLC v. Hyundai Motor America, Inc. et al. (5:2025-cv-00088, W.D. Tex., filed 2025-01-26). Pogona LLC filed a complaint alleging infringement of U.S. Patent No. 11,058,757, among others, against multiple defendants.
  • Pogona LLC v. Kia America, Inc. (6:2025-cv-00045, W.D. Tex., filed 2025-01-19). Pogona LLC also filed a complaint against Kia America, Inc. asserting infringement of U.S. Patent No. 11,058,757, along with other patents.
  • Similar complaints by Pogona LLC asserting U.S. Patent No. 11,058,757 against various defendants have been filed in the Western District of Texas throughout late 2024 and early 2025, common for patent assertion entities like Pogona LLC. These complaints typically seek damages and injunctive relief for alleged infringement. Defendants usually file answers denying infringement and asserting affirmative defenses, including invalidity.

• Pre-Trial Motions:

  • In many of these cases, defendants have filed motions to transfer venue out of the Western District of Texas. For example, in Pogona LLC v. Kia America, Inc., Kia America filed a motion to transfer to the Central District of California (2025-03-25).
  • Motions to stay pending IPR are also common in these cases once an IPR is filed.

• Claim Construction (Markman):

  • Given the relatively recent filing dates of these district court cases (late 2024 / early 2025), it is unlikely that Markman hearings or claim construction orders have been issued in many of these cases yet. The typical timeline for claim construction in the Western District of Texas would place such proceedings later in 2026.

2. PTAB IPR Proceedings (IPR2026-00189)

Unified Patents, an organization known for challenging patents, filed an Inter Partes Review petition against U.S. Patent No. 11,058,757.

• Filing & Initial Pleadings (IPR context):

  • Petition Filing: Unified Patents filed its petition for IPR (IPR2026-00189) on 2026-03-01, challenging the patentability of claims of U.S. Patent No. 11,058,757 owned by Pogona LLC. The petition typically asserts grounds of unpatentability under 35 U.S.C. §§ 102 and/or 103, based on prior art.
  • Patent Owner Preliminary Response Due: Pogona LLC, as the Patent Owner, would have until approximately three months from the filing date to file an optional Patent Owner Preliminary Response, arguing why the IPR should not be instituted. This response would have been due around June 2026.
  • Institution Decision: The PTAB has approximately six months from the filing of the petition to decide whether to institute the IPR. For IPR2026-00189, the institution decision is anticipated by approximately 2026-09-01.

• Current Posture:

  • As of May 29, 2026, IPR2026-00189 is in the pre-institution phase. The PTAB has not yet issued a decision on whether to institute the inter partes review.
  • No final written decision or appeal has occurred, as the case is still in its early stages.

3. Effect of IPR on Litigation:

If the PTAB decides to institute IPR2026-00189, it is highly likely that the district court cases involving U.S. Patent No. 11,058,757 would face motions to stay pending the outcome of the IPR. District courts frequently grant such stays to conserve judicial resources and avoid inconsistent rulings, especially when the IPR has progressed to institution. However, the ultimate decision to grant a stay rests with the district court judge.

Given the early stage of both the IPR and the underlying district court litigations, no final outcomes, settlements, or appeals have been reached in relation to the challenge of U.S. Patent No. 11,058,757 by Unified Patents.

Unified Patents primarily utilizes its in-house legal team of Senior Patent Counsel for inter partes review (IPR) proceedings. While specific counsel for IPR2026-00189 are not yet publicly linked in the provided search results, the following individuals are known to be part of Unified Patents' legal team, specializing in PTAB matters, and are therefore likely to represent the plaintiff in such proceedings:

• Jordan Rossen

  • Role: Senior Patent Counsel, in-house
  • Firm: Unified Patents, Washington, D.C. (though remote officing is possible for Unified Patents' counsel)
  • Experience: Prepares and litigates post-grant proceedings before the PTAB for Unified Patents. Previously practiced in IP litigation at Ropes & Gray and Paul Hastings for eleven years, representing clients before the PTAB, International Trade Commission, district courts, and Federal Circuit in various technology fields.

• David Seastrunk

  • Role: Senior Patent Counsel, in-house
  • Firm: Unified Patents, Washington, D.C. (though remote officing is possible for Unified Patents' counsel)
  • Experience: Prepares and litigates post-grant proceedings before the PTAB for Unified Patents. Prior to joining Unified, he practiced at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, litigating post-grant proceedings, district court cases, and ITC investigations.

• Michelle Callaghan (also referred to as Michelle Aspen in one instance)

  • Role: Senior Patent Counsel, in-house
  • Firm: Unified Patents, Washington, D.C. (though remote officing is possible for Unified Patents' counsel)
  • Experience: Prepares and litigates post-grant proceedings before the PTAB for Unified Patents. Before Unified, she defended clients against patent demands in district courts, challenged patents before the PTAB, and prepared patent validity and infringement opinions at Erise IP across diverse technologies including communication networks and video coding.

• Jung Hahm

  • Role: Senior Patent Counsel, in-house
  • Firm: Unified Patents, Washington, D.C. (though remote officing is possible for Unified Patents' counsel)
  • Experience: Listed as a speaker for Unified Patents webinars on PTAB-related topics.

• Jenn Bisk

  • Role: Senior Patent Counsel, in-house
  • Firm: Unified Patents, Washington, D.C. (though remote officing is possible for Unified Patents' counsel)
  • Experience: Listed as Senior Patent Counsel on the Unified Patents team page.

• Kyla Bulter

  • Role: Senior Patent Counsel, in-house
  • Firm: Unified Patents, Washington, D.C. (though remote officing is possible for Unified Patents' counsel)
  • Experience: Listed as Senior Patent Counsel on the Unified Patents team page.

Unified Patents frequently hires experienced registered patent attorneys with at least five years of experience in PTAB post-grant petitions (IPR, PGR, and CBM) to manage and litigate patent office proceedings internally. Therefore, one or more of these in-house counsel are the likely representatives for Unified Patents in IPR2026-00189. Specific filings for this particular IPR would confirm the exact attorneys of record.

The Patent Owner, Pogona LLC, in IPR2026-00189 is represented by attorneys from Skiermont Derby LLP. While the case caption in the prompt lists Unified Patents as the petitioner, docket information for IPR2026-00189 consistently identifies Pfizer Inc. as the petitioner challenging U.S. Patent 11,058,757.

The counsel of record representing Pogona LLC (referred to as the Patent Owner in IPR proceedings) includes:

• Sarah E. Spires

  • Role: Counsel for Patent Owner (likely lead or significant counsel).
  • Firm: Skiermont Derby LLP, Dallas, Texas.
  • Experience: Spires is a partner at Skiermont Derby LLP, with experience representing patent owners in litigation, including related district court cases involving the same patent.

• Paul J. Skiermont

  • Role: Counsel for Patent Owner (likely lead or significant counsel).
  • Firm: Skiermont Derby LLP, Dallas, Texas.
  • Experience: Skiermont is a founding partner of Skiermont Derby LLP, known for his extensive patent litigation experience. He is listed as an attorney for Pogona, LLC in a parallel district court infringement case concerning the '757 patent.

• Ryan A. Hargrave

  • Role: Counsel for Patent Owner.
  • Firm: Skiermont Derby LLP, Dallas, Texas.
  • Experience: Hargrave is listed as an attorney for Pogona, LLC in related patent litigation concerning the '757 patent.

• Steven W. Hartsell

  • Role: Counsel for Patent Owner.
  • Firm: Skiermont Derby LLP, Dallas, Texas.
  • Experience: Hartsell is listed as an attorney for Pogona, LLC in related patent litigation concerning the '757 patent.

These attorneys are identified as representing Pogona LLC in IPR2026-00189 and in related district court litigation involving U.S. Patent No. 11,058,757.